Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fei Duan

Showing results (261-270 of 276) with videos related to

Pageof 28
Sort By:
The Journal of Clinical Investigation|December 1, 2025
LC3-dependent intercellular transfer of phosphorylated STAT1/2 elicits CXCL9+ macrophages and enhances radiation-induced antitumor immunityJun-Yan Li, Ying-Qing Li, Jia-Hao Dai, et al.
Molecular Cancer|February 3, 2026
Fusobacterium nucleatum manipulates host autophagy to promote its intracellular survival and treatment resistance in nasopharyngeal carcinomaJing-Yun Wang, Ying-Qi Lu, Xi-Rong Tan, et al.
Medcomm|April 3, 2026
Circulating Microbial Metabolites Predict Tumor Relapse and Chemotherapy Efficacy in Nasopharyngeal CarcinomaJun-Yan Li, Yao Yao, Xi-Rong Tan, et al.
Journal of Pain and Symptom Management|November 13, 2025
Physicians' Perspectives and Attitudes Toward Palliative Care for Cancer Children in Mainland ChinaAnan Zhang, Xuan Zhou, Jianmin Wang, et al.
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Nature Communications|November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaMatthew T Campbell, Surena F Matin, Alda L Tam, et al.
Science Translational Medicine|April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapyPavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.
Nature Communications|January 10, 2025
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialPavlos Msaouel, Kai Yu, Ying Yuan, et al.
Science Translational Medicine|July 15, 2026
Culturomics reveals <i>Fusobacterium</i>-<i>Prevotella</i> mutualism as a hallmark of nasopharyngeal tumor microbiotaYing-Qi Lu, Jia-Hao Dai, Yu-Fei Duan, et al.
Pageof 28

Showing results (261-270 of 276) with videos related to

Sort By:
Pageof 28
The Journal of Clinical Investigation|December 1, 2025
LC3-dependent intercellular transfer of phosphorylated STAT1/2 elicits CXCL9+ macrophages and enhances radiation-induced antitumor immunityJun-Yan Li, Ying-Qing Li, Jia-Hao Dai, et al.
Molecular Cancer|February 3, 2026
Fusobacterium nucleatum manipulates host autophagy to promote its intracellular survival and treatment resistance in nasopharyngeal carcinomaJing-Yun Wang, Ying-Qi Lu, Xi-Rong Tan, et al.
Medcomm|April 3, 2026
Circulating Microbial Metabolites Predict Tumor Relapse and Chemotherapy Efficacy in Nasopharyngeal CarcinomaJun-Yan Li, Yao Yao, Xi-Rong Tan, et al.
Journal of Pain and Symptom Management|November 13, 2025
Physicians' Perspectives and Attitudes Toward Palliative Care for Cancer Children in Mainland ChinaAnan Zhang, Xuan Zhou, Jianmin Wang, et al.
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Nature Communications|November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaMatthew T Campbell, Surena F Matin, Alda L Tam, et al.
Science Translational Medicine|April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapyPavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.
Nature Communications|January 10, 2025
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialPavlos Msaouel, Kai Yu, Ying Yuan, et al.
Science Translational Medicine|July 15, 2026
Culturomics reveals <i>Fusobacterium</i>-<i>Prevotella</i> mutualism as a hallmark of nasopharyngeal tumor microbiotaYing-Qi Lu, Jia-Hao Dai, Yu-Fei Duan, et al.
Pageof 28